Literature DB >> 12842618

Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay.

Craig J Morton1, Rachel Cameron, Lynne J Lawrence, Bo Lin, Melinda Lowe, Angela Luttick, Anthony Mason, Jenny McKimm-Breschkin, Michael W Parker, Jane Ryan, Michael Smout, Jayne Sullivan, Simon P Tucker, Paul R Young.   

Abstract

Respiratory syncytial virus (RSV) is a ubiquitous human pathogen and the leading cause of lower respiratory tract infections in infants. Infection of cells and subsequent formation of syncytia occur through membrane fusion mediated by the RSV fusion protein (RSV-F). A novel in vitro assay of recombinant RSV-F function has been devised and used to characterize a number of escape mutants for three known inhibitors of RSV-F that have been isolated. Homology modeling of the RSV-F structure has been carried out on the basis of a chimera derived from the crystal structures of the RSV-F core and a fragment from the orthologous fusion protein from Newcastle disease virus (NDV). The structure correlates well with the appearance of RSV-F in electron micrographs, and the residues identified as contributing to specific binding sites for several monoclonal antibodies are arranged in appropriate solvent-accessible clusters. The positions of the characterized resistance mutants in the model structure identify two promising regions for the design of fusion inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842618     DOI: 10.1016/s0042-6822(03)00115-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  The human respiratory syncytial virus matrix protein is required for maturation of viral filaments.

Authors:  Ruchira Mitra; Pradyumna Baviskar; Rebecca R Duncan-Decocq; Darshna Patel; Antonius G P Oomens
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  The respiratory syncytial virus fusion protein targets to the perimeter of inclusion bodies and facilitates filament formation by a cytoplasmic tail-dependent mechanism.

Authors:  Pradyumna S Baviskar; Anne L Hotard; Martin L Moore; Antonius G P Oomens
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

3.  Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.

Authors:  Song Feng; Di Hong; Baoxia Wang; Xiufang Zheng; Kun Miao; Lisha Wang; Hongying Yun; Lu Gao; Shuhai Zhao; Hong C Shen
Journal:  ACS Med Chem Lett       Date:  2015-01-25       Impact factor: 4.345

4.  Role of the simian virus 5 fusion protein N-terminal coiled-coil domain in folding and promotion of membrane fusion.

Authors:  Dava S West; Michael S Sheehan; Patrick K Segeleon; Rebecca Ellis Dutch
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency.

Authors:  Rosemary S Harrison; Nicholas E Shepherd; Huy N Hoang; Gloria Ruiz-Gómez; Timothy A Hill; Russell W Driver; Vishal S Desai; Paul R Young; Giovanni Abbenante; David P Fairlie
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-11       Impact factor: 11.205

6.  The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion.

Authors:  Imogen M Bermingham; Keith J Chappell; Daniel Watterson; Paul R Young
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

7.  RNA interference as a potential therapeutic treatment for inflammation associated lung injury.

Authors:  Joanne Lomas-Neira; Chun-Shiang Chung; Alfred Ayala
Journal:  Int J Clin Exp Med       Date:  2008-02-25

8.  Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.

Authors:  Mari Numata; Hong Wei Chu; Azzeddine Dakhama; Dennis R Voelker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

9.  Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.

Authors:  Dan Yan; Sujin Lee; Vidhi D Thakkar; Ming Luo; Martin L Moore; Richard Karl Plemper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

10.  The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation.

Authors:  Chetan D Meshram; Pradyumna S Baviskar; Cherie M Ognibene; Antonius G P Oomens
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.